Bank of Montreal Can Buys 71,575 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Bank of Montreal Can increased its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 9,442.6% during the 2nd quarter, Holdings Channel reports. The fund owned 72,333 shares of the biopharmaceutical company’s stock after acquiring an additional 71,575 shares during the period. Bank of Montreal Can’s holdings in Amicus Therapeutics were worth $1,145,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of FOLD. First Trust Advisors LP bought a new position in Amicus Therapeutics during the first quarter worth $635,000. BlackRock Inc. grew its holdings in shares of Amicus Therapeutics by 1.8% during the first quarter. BlackRock Inc. now owns 21,239,016 shares of the biopharmaceutical company’s stock valued at $196,248,000 after buying an additional 382,909 shares during the last quarter. State Board of Administration of Florida Retirement System increased its position in shares of Amicus Therapeutics by 17.8% during the first quarter. State Board of Administration of Florida Retirement System now owns 102,957 shares of the biopharmaceutical company’s stock worth $951,000 after acquiring an additional 15,540 shares in the last quarter. Arizona State Retirement System acquired a new stake in shares of Amicus Therapeutics in the 1st quarter worth about $553,000. Finally, Rhumbline Advisers lifted its position in Amicus Therapeutics by 4.2% in the 1st quarter. Rhumbline Advisers now owns 372,187 shares of the biopharmaceutical company’s stock valued at $3,439,000 after acquiring an additional 15,150 shares in the last quarter.

Amicus Therapeutics stock opened at $13.91 on Wednesday. Amicus Therapeutics, Inc. has a 12 month low of $6.25 and a 12 month high of $16.13. The company has a current ratio of 3.54, a quick ratio of 3.42 and a debt-to-equity ratio of 0.42. The business’s 50 day simple moving average is $14.39 and its 200 day simple moving average is $12.57. The company has a market cap of $3.60 billion, a price-to-earnings ratio of -12.20 and a beta of 1.18.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Monday, August 10th. The biopharmaceutical company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.06. Amicus Therapeutics had a negative return on equity of 65.53% and a negative net margin of 129.10%. The business had revenue of $62.35 million for the quarter, compared to the consensus estimate of $62.66 million. As a group, equities research analysts forecast that Amicus Therapeutics, Inc. will post -1 earnings per share for the current fiscal year.

In other Amicus Therapeutics news, COO Bradley L. Campbell sold 12,500 shares of the stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $15.47, for a total transaction of $193,375.00. Following the sale, the chief operating officer now owns 351,264 shares in the company, valued at $5,434,054.08. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Jay Barth sold 28,750 shares of the stock in a transaction on Monday, August 31st. The stock was sold at an average price of $14.74, for a total value of $423,775.00. Following the sale, the insider now owns 191,954 shares in the company, valued at approximately $2,829,401.96. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 477,374 shares of company stock worth $7,394,630. Company insiders own 2.30% of the company’s stock.

A number of brokerages have commented on FOLD. Citigroup boosted their price objective on Amicus Therapeutics from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Amicus Therapeutics in a report on Monday, June 8th. SVB Leerink reaffirmed a “market perform” rating and issued a $19.00 target price on shares of Amicus Therapeutics in a report on Tuesday, May 19th. BTIG Research assumed coverage on Amicus Therapeutics in a report on Tuesday, June 16th. They issued a “buy” rating and a $19.00 target price for the company. Finally, BidaskClub raised Amicus Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, September 10th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eight have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $19.85.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.

Further Reading: What is insider trading?

Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD).

Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.